2023 Tuberculosis Drug Discovery and Development Gordon Research Conference and Gordon Research Seminar
2023结核病药物发现与开发戈登研究大会暨戈登研究研讨会
基本信息
- 批准号:10675238
- 负责人:
- 金额:$ 0.6万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-07-11 至 2023-11-30
- 项目状态:已结题
- 来源:
- 关键词:AddressArchitectureAreaAutomobile DrivingBacterial InfectionsBiologyBudgetsCOVID-19Cessation of lifeChemicalsClinicalClinical TrialsClinical Trials DesignCollaborationsCommunicable DiseasesCommunitiesComplexCountryCoupledDataDevelopmentDisclosureDiseaseDrug CombinationsDrug IndustryDrug resistanceDrug resistance in tuberculosisEnvironmentEvaluationFaceFacultyFosteringFunding AgencyGeographyGoalsGrowthHealth PrioritiesHourHumanIncomeIndustrializationInfectious AgentInjectableInstitutionInternationalLeadLearningLeisuresLocationMentorsMethodsMultidrug-Resistant TuberculosisMycobacterium tuberculosisOralParticipantPerformancePharmaceutical PreparationsPharmacologic SubstancePlayPostdoctoral FellowPrivatizationRegimenResearchResearch PersonnelScienceScientistSeriesSiteSocializationSpainSpeedStructureStudentsTechnologyTimeTrainingTranslational ResearchTuberculosisUnderrepresented MinorityUnited States National Institutes of HealthWomancareercareer developmentdesigndrug developmentdrug discoverydrug efficacydrug-sensitiveearly-career facultyfightingglobal healthimprovedinnovationinsightmeetingsnew technologynext generationnovelnovel strategiesnovel therapeuticspandemic diseaseprematurepreventprogramsresearch studyside effectsuccesssymposiumtuberculosis chemotherapytuberculosis drugstuberculosis treatment
项目摘要
ABSTRACT
This application seeks support for the 2023 Tuberculosis (TB) Drug Discovery & Development Gordon Research
Conference (GRC) and Gordon Research Seminar (GRS) to be held in at the Rey Don Jaime Grand Hotel in
Castelldefels, Spain from July 22-23 and July 23 – 28, 2023. This will be the eleventh GRC on TB Drug discovery
(with the first being held in 2001 and thereafter on a biennial basis) and the fifth GRS associated with this GRC.
For more than 20 years this conference series has held a unique place in the global portfolio of TB research
conferences. For many years it has been oversubscribed, been rated above average by more than 70% of
attendees and received a high-performance rating in the GRC Evaluation. Among the factors that makes this
conference series stand out are its rigorous focus on TB drug development, the emphasis on presentation of
unpublished data (enabled by the strictly enforced rules against recording or photographing of presentations),
the disclosure of novel hit and lead compounds, the large fraction of attendees from the pharmaceutical industry,
and the well-attended networking sessions.
The overall theme for this GRC is “Leads, technologies and clinical trials for new TB drug regimens”. The
conference will discuss and disclose recently developed lead molecules as well as new technologies and
approaches to clinical trials, debate how recent insight into TB biology and performance of clinical drug
combinations may facilitate identifying leads and improving regimens, review how new technologies and trial
innovations can identify improved drug regimens, and discuss how to capitalize on successes in other disease
areas. The focus of this conference is thus quite different from the most recent conference in this series, which
centered around treatment shortening and was held in 2019.
The GRC and associated GRS foster an environment wherein which researchers are encouraged to share
cutting edge unpublished data and exchange ideas between both established and young investigators and
trainees hereby promoting career development for all attendees. The GRC will include a “Power Hour”, an
optional gathering for all meeting participants to address the challenges underrepresented minorities and women
face in science and to support their professional growth. Both the GRC and the GRS programs will reflect the
diversity of the scientists in the field with an aim of strong representation of women, underrepresented minorities,
and international scientists. GRCs are unique in facilitating multiple opportunities for informal interactions
between researchers from different sectors, geographies, and career stages, often resulting in exchanges
leading to new collaborations. In this pandemic era, such opportunities have become rare and thus even more
important to driving forward innovation in research.
摘要
该申请寻求对2023年结核病(TB)药物发现和开发戈登研究的支持
会议(GRC)和戈登研究研讨会(GRS)将在雷伊唐海梅大酒店举行,
Castelldefels,西班牙,2023年7月22日至23日和7月23日至28日这将是结核病药物发现的第十一次GRC
(with第一次于2001年举行,其后每两年举行一次),以及与本研讨会有关的第五次研讨会。
20多年来,这一系列会议在全球结核病研究领域占有独特的地位
两会多年来,它一直被超额认购,超过70%的人认为它高于平均水平。
并在GRC评估中获得了高绩效评级。在这些因素中,
会议系列突出的是其严格的重点是结核病药物的开发,重点介绍
未发布的数据(通过严格执行禁止录制或拍摄演示文稿的规则),
新的命中和先导化合物的公开,来自制药工业的大部分与会者,
以及出席率很高的网络会议。
本次研讨会的总体主题是“新型结核病药物治疗方案的先导、技术和临床试验”。的
会议将讨论和披露最近开发的铅分子以及新技术,
临床试验的方法,争论最近对结核病生物学的认识和临床药物的性能
联合用药可能有助于识别先导药物和改善治疗方案,审查新技术和试验
创新可以确定改进的药物治疗方案,并讨论如何利用在其他疾病中的成功,
地区因此,本次会议的重点与本系列中最近的一次会议大不相同,
以缩短治疗时间为中心,于2019年举行。
GRC和相关的GRS营造了一个鼓励研究人员分享的环境
尖端未发表的数据和交流思想之间的既定和年轻的研究人员,
学员借此促进所有与会者的职业发展。GRC将包括一个“电源小时”,
所有与会者可选择参加的聚会,以应对代表性不足的少数群体和妇女面临的挑战
面对科学,并支持他们的专业成长。GRC和GRS计划都将反映
该领域科学家的多样性,目标是妇女、代表性不足的少数民族、
国际科学家。GRCs在促进非正式互动的多种机会方面是独一无二的
来自不同部门、地理位置和职业阶段的研究人员之间进行交流,
导致新的合作。在这个大流行的时代,这样的机会已经变得罕见,
这对推动研究创新至关重要。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Dirk Schnappinger其他文献
Dirk Schnappinger的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Dirk Schnappinger', 18)}}的其他基金
Project 2. Acquisition, synthesis and importance of biotin in Mtb.
项目 2. 结核分枝杆菌中生物素的获取、合成及其重要性。
- 批准号:
10426180 - 财政年份:2020
- 资助金额:
$ 0.6万 - 项目类别:
Project 2. Acquisition, synthesis and importance of biotin in Mtb.
项目 2. 结核分枝杆菌中生物素的获取、合成及其重要性。
- 批准号:
10190814 - 财政年份:2020
- 资助金额:
$ 0.6万 - 项目类别:
Project 2. Acquisition, synthesis and importance of biotin in Mtb.
项目 2. 结核分枝杆菌中生物素的获取、合成及其重要性。
- 批准号:
10641879 - 财政年份:2020
- 资助金额:
$ 0.6万 - 项目类别:
相似海外基金
Practical Study on Disaster Countermeasure Architecture Model by Sustainable Design in Asian Flood Area
亚洲洪泛区可持续设计防灾建筑模型实践研究
- 批准号:
17K00727 - 财政年份:2017
- 资助金额:
$ 0.6万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Functional architecture of a face processing area in the common marmoset
普通狨猴面部处理区域的功能架构
- 批准号:
9764503 - 财政年份:2016
- 资助金额:
$ 0.6万 - 项目类别:
SBIR Phase II: Area and Energy Efficient Error Floor Free Low-Density Parity-Check Codes Decoder Architecture for Flash Based Storage
SBIR 第二阶段:用于基于闪存的存储的面积和能源效率高、无错误层的低密度奇偶校验码解码器架构
- 批准号:
1632562 - 财政年份:2016
- 资助金额:
$ 0.6万 - 项目类别:
Standard Grant
Heating and airconditioning by hypocausts in residential and representative architecture in Rome and Latium studies of a phenomenon of luxury in a favoured climatic area of the Roman Empire on the basis of selected examples.
罗马和拉齐奥的住宅和代表性建筑中的火烧供暖和空调根据选定的例子,研究了罗马帝国有利的气候地区的奢华现象。
- 批准号:
317469425 - 财政年份:2016
- 资助金额:
$ 0.6万 - 项目类别:
Research Grants
SBIR Phase I: Area and Energy Efficient Error Floor Free Low-Density Parity-Check Codes Decoder Architecture for Flash Based Storage
SBIR 第一阶段:用于基于闪存的存储的面积和能源效率高、无错误层低密度奇偶校验码解码器架构
- 批准号:
1520137 - 财政年份:2015
- 资助金额:
$ 0.6万 - 项目类别:
Standard Grant
A Study on The Spatial Setting and The Inhavitant's of The Flood Prevention Architecture in The Flood Area
洪泛区防洪建筑空间设置及居民生活研究
- 批准号:
26420620 - 财政年份:2014
- 资助金额:
$ 0.6万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Area and power efficient interconnect architecture for multi-bit processing on FPGAs
用于 FPGA 上多位处理的面积和功率高效互连架构
- 批准号:
327691-2007 - 财政年份:2011
- 资助金额:
$ 0.6万 - 项目类别:
Discovery Grants Program - Individual
A FUNDAMENTAL STUDY ON UTILIZATION OF THE POST-WAR ARCHITECTURE AS URBAN REGENERATION METHOD, A case of the central area of Osaka city
战后建筑作为城市更新方法的基础研究——以大阪市中心区为例
- 批准号:
22760469 - 财政年份:2010
- 资助金额:
$ 0.6万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Area and power efficient interconnect architecture for multi-bit processing on FPGAs
用于 FPGA 上多位处理的面积和功率高效互连架构
- 批准号:
327691-2007 - 财政年份:2010
- 资助金额:
$ 0.6万 - 项目类别:
Discovery Grants Program - Individual
Area and power efficient interconnect architecture for multi-bit processing on FPGAs
用于 FPGA 上多位处理的面积和功率高效互连架构
- 批准号:
327691-2007 - 财政年份:2009
- 资助金额:
$ 0.6万 - 项目类别:
Discovery Grants Program - Individual